Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Alarming new "superbug" gene found in animals and people in China

Published 11/18/2015, 06:34 PM
Updated 11/18/2015, 06:40 PM
Alarming new "superbug" gene found in animals and people in China

By Kate Kelland

LONDON, (Reuters) - A new gene that makes bacteria highly resistant to a last-resort class of antibiotics has been found in people and pigs in China - including in samples of bacteria with epidemic potential, researchers said on Wednesday.

The discovery was described as "alarming" by scientists, who called for urgent restrictions on the use of polymyxins - a class of antibiotics that includes the drug colistin and is widely used in livestock farming.

"All use of polymyxins must be minimized as soon as possible and all unnecessary use stopped," said Laura Piddock, a professor of microbiology at Britain's Birmingham University who was asked to comment on the finding.

Researchers led by Hua Liu from the South China Agricultural University who published their work in the Lancet Infectious Diseases journal found the gene, called mcr-1, on plasmids - mobile DNA that can be easily copied and transferred between different bacteria.

This suggests "an alarming potential" for it to spread and diversify between bacterial populations, they said.

The team already has evidence of the gene being transferred between common bacteria such as E.coli, which causes urinary tract and many other types of infection, and Klesbsiella pneumoniae, which causes pneumonia and other infections.

This suggests "the progression from extensive drug resistance to pandrug resistance is inevitable," they said.

"(And) although currently confined to China, mcr-1 is likely to emulate other resistance genes ... and spread worldwide."

INDIAN PRECEDENT

The discovery of the spreading mcr-1 resistance gene echoes news from 2010 of another so-called "superbug" gene, NDM-1, which emerged in India and rapidly spread around the world.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Piddock and others said global surveillance for mcr-1 resistance is now essential to try to prevent the spread of polymyxin-resistant bacteria.

China is one of the world's largest users and producers of colistin for agriculture and veterinary use.

Worldwide demand for the antibiotic in agriculture is expected to reach almost 12,000 tonnes per year by the end of 2015, rising to 16,500 tonnes by 2021, according to a 2015 report by the QYResearch Medical Research Center.

In Europe, 80 percent of polymixin sales - mainly colistin - are in Spain, Germany and Italy, according to the European Medicines Agency's Surveillance of Veterinary Antimicrobial Consumption (ESVAC) report.

For the China study, researchers collected bacteria samples from pigs at slaughter across four provinces, and from pork and chicken sold in 30 open markets and 27 supermarkets in Guangzhou between 2011 and 2014. They also analyzed bacteria from patients with infections at two hospitals in Guangdong and Zhejiang.

They found a high prevalence of the mcr-1 gene in E coli samples from animals and raw meat. Worryingly, the proportion of positive samples increased from year to year, they said, and mcr-1 was also found in 16 E.coli and K.pneumoniae samples from 1,322 hospitalized patients.

David Paterson and Patrick Harris from Australia's University of Queensland, writing a commentary in the same journal, said the links between agricultural use of colistin, colistin resistance in slaughtered animals, colistin resistance in food, and colistin resistance in humans were now complete.

"One of the few solutions to uncoupling these connections is limitation or cessation of colistin use in agriculture," they said. "Failure to do so will create a public health problem of major dimensions."

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.